James K McCloskey, MD, Jamie L Koprivnikar, MD, and Christina Cho, MD discuss the diagnosis of myelodysplastic syndrome (MDS) and the importance of risk stratification in guiding treatment decisions.
Safusidenib showed durable responses in IDH1-mutant glioma, and ongoing trials will test the agent in oligodendroglioma, after vorasidenib, and as maintenance.
In the phase 1/2 TRANSCEND CLL 004 trial, liso-cel plus ibrutinib produced a 45% CR/CRi rate in a heavily pretreated relapsed/refractory CLL/SLL population.